JPRN-UMIN000025112
Not yet recruiting
未知
Clinical efficacy of Liquid biopsy for acquired resistance to afatinib in EGFR positive NSCLC - Liquid biopsy for acquired resistance to afatinib
ConditionsEGFR mutation positive NSCLC
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- EGFR mutation positive NSCLC
- Sponsor
- Aichi cancer center
- Enrollment
- 100
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Investigation on the usefulness of liquid biopsy for tumor-derived circulating DNA in patients with EGFR-mutant NSCLC during and after treatment with EGFR-TKIson-small cell Lung CancerJPRN-UMIN000023248PHRF122
Active, not recruiting
Phase 1
tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code: 10025055Term: Lung cancer non-small cell stage IV Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2024-511317-38-00Fundacion GECP33
Active, not recruiting
Phase 1
tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-002369-36-ESFundación GECP30
Recruiting
Not Applicable
Research on Liquid Biopsy in Patients with Gastrointestinal and Abdominal Malignancies, Including Colorectal Cancernresectable advanced or reccurrent gastrointestinal malignanciesJPRN-UMIN000029315ational Cancer Center Hospital East7,000
Recruiting
Not Applicable
Exploratory research of liquid biopsy for patients with cancercancerJPRN-UMIN000033269Cancer Precision Medicine Center Cancer Institute,800